(Total Views: 525)
Posted On: 03/15/2018 4:40:07 PM
Post# of 30066
I had such high hopes for that JNJ incubation opportunity at Janssen Labs.
Unfortunately we ended up like the majority in that situation with no deal.
Hind sight is 20/20 but not going anywhere with that opportunity was probably a clue that I was looking at this through rose colored glasses. If JNJ smells a near term winner they don’t tend to let them leave the Lab without a deal. If they think it’s a long term winner they continue to provide the space.
I still think ESS is the only near term catalyst. I keep thinking that there must be an additional barrier other than needing money to set up trials for this to be taking so long. Several Wound Care companies should be lining up to partner. The fact that none are concerns me. Wound care is about a $13 bil market just in the US.
Unfortunately we ended up like the majority in that situation with no deal.
Hind sight is 20/20 but not going anywhere with that opportunity was probably a clue that I was looking at this through rose colored glasses. If JNJ smells a near term winner they don’t tend to let them leave the Lab without a deal. If they think it’s a long term winner they continue to provide the space.
I still think ESS is the only near term catalyst. I keep thinking that there must be an additional barrier other than needing money to set up trials for this to be taking so long. Several Wound Care companies should be lining up to partner. The fact that none are concerns me. Wound care is about a $13 bil market just in the US.
(3)
(0)
